HALOZYME THERAPEUTICS INC
704 institutions still hold HALOZYME THERAPEUTICS INC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
The largest number in Halozyme's institutional quarter — Assenagon Asset Management's $76.7 million add — is also the least informative: Assenagon is a quasi-passive options-overlay manager whose blocks swing mechanically across hundreds of names, and its stake here should be read as hedging inventory rather than a biotech view. The quarter's real event is the arrival of over $40 million in discretionary new money: WEDGE Capital initiated a $31.6 million position — instantly the third-largest tracked holding — while Augustine Asset Management ($4.8 million) and Australia's Cooper Investors ($4.3 million) opened positions of their own. Congress Asset Management, the largest tracked holder at $96.2 million, trimmed shares even as price appreciation grew the position's dollar value. Selling elsewhere was negligible: the biggest genuine reduction was $659,000.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.